Healthcare · NIFTY 500

Wockhardt Limited

NSEWOCKPHARMA BSE532300 ISININE049B01025 SeriesEQ Listed on NSE · BSE · MSEI

₹2,054.00 +19.40 (+0.95%) Updated 12 Nov, 8:49 pm IST

Open chart Back to screener

Price, daily close+42.61% in a year

Today

Open: ₹2,034.60
Prev close: ₹2,034.60
Day high: ₹2,064.00
Day low: ₹2,025.00
Volume: 3.43 L
Value traded: ₹70.19 Cr
Upper circuit: ₹2,441.50
Lower circuit: ₹1,627.70
52W high: ₹2,422.30
52W low: ₹1,086.70
1 month: -4.07%
6 months: +19.77%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹33,275 Cr

P/E (TTM)81.41

P/B6.45

Book value / share₹318.40

EPS (TTM)₹25.23

ROE7.9%

Dividend yield—

Dividend (12m)—

Net margin (TTM)10.9%

Operating margin17.9%

Debt / equity0.42

Current ratio1.55

EV / EBITDA45.05

Sales growth (YoY qtr)+23.91%

Profit growth (YoY qtr)+1.28%

Sales CAGR 3Y+8.36%

Profit CAGR 3Y—

Shares16.20 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

701-83.0

Dec 23

700-169

Mar 24

739-14.0

Jun 24

809-22.0

Sep 24

72114.0

Dec 24

743-25.0

Mar 25

738-90.0

Jun 25

78278.0

Sep 25

88859.0

Dec 25

965166

Mar 26

929106

Jun 26

96979.0

Sep 26

Revenue · QoQ (vs last quarter)

—-0.1%+5.6%+9.5%-11%+3.1%-0.7%+6.0%+14%+8.7%-3.7%+4.3%

Revenue · YoY (vs a year ago)

————+2.9%+6.1%-0.1%-3.3%+23%+30%+26%+24%

Net profit · QoQ (vs last quarter)

—-104%+92%-57%+164%-279%-260%+187%-24%+181%-36%-25%

Net profit · YoY (vs a year ago)

————+117%+85%-543%+455%+321%+764%+218%+1.3%

RevenueNet profitLine = trend

-5.75

Dec 23

-11.64

Mar 24

-0.95

Jun 24

-1.47

Sep 24

0.91

Dec 24

-1.57

Mar 25

-5.53

Jun 25

4.81

Sep 25

3.61

Dec 25

10.22

Mar 26

6.55

Jun 26

4.85

Sep 26

EPS (₹) · YoY (vs a year ago)

————+116%+87%-482%+427%+297%+751%+218%+0.8%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	701	700	739	809	721	743	738	782	888	965	929	969
Other income	8.0	54.0	30.0	9.0	8.0	15.0	20.0	21.0	25.0	45.0	31.0	11.0
Total income	709	754	769	818	729	758	758	803	913	1,010	960	980
Raw material	160	144	150	182	121	159	168	159	170	177	233	243
Purchases	150	154	153	150	122	148	140	129	161	156	109	123
Employee cost	152	157	160	161	164	166	171	186	181	187	203	201
Other expenses	210	352	175	241	167	253	231	185	213	235	214	254
Total expenses	796	934	775	827	708	780	770	712	836	843	844	907
Operating profit	37.0	-103	91.0	110	128	64.0	-25.0	178	167	247	192	173
OPM %	5.3%	-14.7%	12.3%	13.6%	17.8%	8.6%	-3.4%	22.8%	18.8%	25.6%	20.7%	17.9%
Finance cost	77.0	73.0	73.0	73.0	60.0	48.0	48.0	55.0	60.0	50.0	52.0	56.0
Depreciation	55.0	58.0	54.0	55.0	55.0	53.0	56.0	53.0	65.0	53.0	55.0	55.0
Exceptional items	—	—	—	—	—	—	-97.0	—	-10.0	22.0	—	—
Profit before tax	-87.0	-180	-6.0	-9.0	21.0	-22.0	-109	91.0	67.0	189	116	73.0
Tax	-1.0	-3.0	10.0	7.0	1.0	23.0	-1.0	9.0	6.0	25.0	9.0	0.0
Net profit	-86.0	-177	-16.0	-16.0	20.0	-45.0	-108	82.0	61.0	164	107	73.0
Profit to shareholders	-83.0	-169	-14.0	-22.0	14.0	-25.0	-90.0	78.0	59.0	166	106	79.0
EPS (₹)	-5.75	-11.64	-0.95	-1.47	0.91	-1.57	-5.53	4.81	3.61	10.22	6.55	4.85

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

4,158110-195

FY19

2,844119-69.2

FY20

2,708-206686

FY21

3,230115-244

FY22

2,651-193-559

FY23

2,79825.0-463

FY24

3,012393-47.0

FY25

3,373567213

FY26

Revenue · YoY (vs a year ago)

—-32%-4.8%+19%-18%+5.5%+7.6%+12%

Net profit · YoY (vs a year ago)

—+64%+1,091%-136%-129%+17%+90%+553%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	4,158	2,844	2,708	3,230	2,651	2,798	3,012	3,373
Other income	21.0	38.8	132	20.0	122	83.0	62.0	111
Total expenses	4,480	3,225	3,266	3,478	3,103	3,287	3,090	3,161
Employee cost	937	743	763	749	637	629	651	725
Operating profit	110	119	-206	115	-193	25.0	393	567
OPM %	2.6%	4.2%	-7.6%	3.6%	-7.3%	0.9%	13.0%	16.8%
Finance cost	265	276	249	299	302	305	254	213
Depreciation	166	224	246	247	251	223	217	227
Profit before tax	-300	-342	-568	-411	-624	-420	-16.0	238
Tax	-83.7	-204	-272	-132	-3.0	52.0	41.0	39.0
Tax rate %	—	—	—	—	—	—	—	16.4%
Net profit	-217	-43.4	689	-279	-621	-472	-57.0	199
Profit to shareholders	-195	-69.2	686	-244	-559	-463	-47.0	213
Net margin %	-4.7%	-2.4%	25.3%	-7.6%	-21.1%	-16.5%	-1.6%	6.3%
EPS (₹)	-17.58	-6.29	61.56	-20.24	-38.79	-32.05	-3.02	13.10

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

3,3541,88790.0

Mar 23

3,3592,112505

Mar 24

4,3531,859112

Mar 25

4,9402,125217

Mar 26

5,1582,150330

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+0.1%+30%+13%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	3,354	3,359	4,353	4,940	5,158
Long-term borrowings	224	891	1,211	1,518	1,431
Short-term borrowings	1,663	1,221	648	607	719
Total borrowings	1,887	2,112	1,859	2,125	2,150
Current liabilities	3,435	2,791	2,042	1,622	1,785
Fixed assets (PPE)	2,022	1,875	1,718	1,618	1,601
Inventories	658	640	725	887	973
Trade receivables	797	618	661	588	632
Cash & equivalents	90.0	505	112	217	330
Current assets	1,914	2,073	2,465	2,606	2,764
Total assets	7,683	7,649	8,135	8,615	8,902
Debt / equity	0.56	0.63	0.43	0.43	0.42

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

413-201-71.0

FY22

153-125-315

FY23

219-137334

FY24

-22.0-783409

FY25

390-241-54.0

FY26

Operations · YoY (vs a year ago)

—-63%+43%-110%+1,873%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	413	153	219	-22.0	390
Cash from investing	-201	-125	-137	-783	-241
Cash from financing	-71.0	-315	334	409	-54.0
Spent on fixed assets	-118	-42.0	-59.0	-94.0	-136
Free cash flow	295	111	160	-116	254
Net cash flow	141	-287	416	-396	95.0

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

51.6%Mar 24

52.0%Jun 24

52.0%Sep 24

49.1%Nov 24

49.1%Dec 24

49.1%Mar 25

49.1%Jun 25

49.1%Sep 25

49.1%Dec 25

49.1%Mar 26

49.1%Jun 26

49.3%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

49.3%promoter

Promoter & group: 49.32%
Public (FIIs, mutual funds, retail…): 50.68%
Promoter change, last quarter: +0.24 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Annual General MeetingEx 21-Jun-2024
Annual General MeetingEx 07-Aug-2023
Rights 3:10@ Premium Rs 220 Per ShareEx 08-Mar-2022
Annual General MeetingEx 23-Jul-2021
Annual General MeetingEx 24-Jul-2020
Annual General MeetingEx 02-Aug-2019
Annual General MeetingEx 25-Jul-2018
Annual General MeetingEx 24-Jul-2017

Board meetings

WOCKHARDT LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial …02-Nov-2026
the financial results for the period ended September 30, 202602-Nov-2026
WOCKHARDT LIMITED has informed the Exchange about Board Meeting to be held on 10-Aug-2026 to inter-alia consider and approve the Unaudited Financial …10-Aug-2026
the Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2026.10-Aug-2026
the Yearly Audited Financial results of the Company for the period ended March 2026 and Fund raising.04-May-2026

Filings with NSE

Cessation9 Nov
Monitoring Agency Report2 Nov
Change in Management2 Nov
Press Release2 Nov
Outcome of Board Meeting2 Nov
ESOP/ESOS/ESPS27 Oct
Copy of Newspaper Publication24 Oct

Latest news

Sun Pharma, Divi’s Lab, Wockhardt: Pharma stocks surge up to 8% during Muhurat Trading session; why did stocks rally today?Upstox · 8 Nov, 3:10 pm Wockhardt shares rise 7%, extend gains for fourth consecutive sessionCNBC TV18 · 7 Sep, 12:30 pm How Wockhardt solved a problem Indian pharma couldn'tFinshots · 4 Jun, 12:30 pm Wockhardt Share Price Fall Streak: Sector SnapshotUnivest · 13 Oct, 12:30 pm Five Stocks To Buy Today: Piramal Pharma, Wockhardt, CG Power, And More | August 28NDTV Profit · 28 Aug, 12:30 pm Wockhardt Share Price Today Down 7%Equitymaster · 2 Jun, 12:30 pm Wockhardt soars 19%, zooms 75% in 1 month; what's driving pharma stock?Business Standard · 1 Jun, 12:30 pm Wockhardt stock soars up to 16% as US FDA clears novel antibiotic ZaynichMoneycontrol.com · 1 Jun, 12:30 pm

About

About Wockhardt Limited

Wockhardt Limited is an Indian pharmaceutical and biotechnology company headquartered in Mumbai. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company has manufacturing plants in India, the UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Wockhardt Limited
NSE symbol: WOCKPHARMA
BSE scrip code: 532300
ISIN: INE049B01025
Listed on: NSE, BSE, MSEI
Series: EQ (normal equity)
Listed on NSE since: 23 Feb 2000
Face value: ₹5 per share
Market lot: 1 share
Shares issued: 16.20 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Murtaza Khorakiwala
Chair: Habil Khorakiwala
Headquarters: Mumbai, Maharashtra, India
Registered address: Wockhardt Towers, Bandra Kurla Complex, Bandra (East),Mumbai, Maharashtra, 400 051
Founded: 1960
Employees: 4,084
Financial year: April to March
Results basis: Consolidated
Website: wockhardt.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Wockhardt Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers